SiteOne Therapeutics
South San Francisco
About SiteOne Therapeutics
SiteOne Therapeutics is a biopharmaceutical company that develops novel therapeutics and diagnostics. They develop products that safely, effectively, and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Their lead therapeutic candidates are highly selective inhibitors of a voltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $134.2M
- Funding stage: M&A
- Last round: Series C (Dec 2024)
- Website: siteonetherapeutics.com
- Phone: +1 (406) 602-4558
Industries & Categories
Biotechnology, Health Diagnostics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/siteone-therapeutics-27936 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.